Update on the clinical utility of once-daily tacrolimus in the management of transplantation

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1183-1194

  Salas, Maria Aurora Posadas ^a   Srinivas, Titte R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adherence; Immunosuppression; Pharmacokinetics; Toxicity

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; BIOEQUIVALENCE; BIOPSY PROVEN ACUTE REJECTION; BLOOD PRESSURE; CLINICAL PRACTICE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG UTILIZATION; DYSLIPIDEMIA; GLUCOSE METABOLISM; GRAFT SURVIVAL; HEADACHE; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPID METABOLISM; LIVER TRANSPLANTATION; LONG TERM CARE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); NAUSEA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TREMOR; URINARY TRACT INFECTION; PROCEDURES;

HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; TACROLIMUS;

EID: 84908068625     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S55458     Document Type: Review

References (41)

1. Kaplan B, Srinivas TR, Meier-Kriesche HU. Factors associated with long-term renal allograft survival. Ther Drug Monit. 2002;24(1): 36-39.
2. van Boekel GA, Kerkhofs CH, Hilbrands LB. Treatment satisfaction in renal transplant patients taking tacrolimus once daily. Clin Ther. 2013;35(11):1821-1829. e1.
3. United States Organ Transplantation. OPTN/SRTR 2012 Annual Data Report [webpage on the Internet]. US Department of Health and Human Services; 2014. Available from: http://srtr.transplant.hrsa.gov/annual_reports/2012/flash/2012_SRTR_ADR/index.html. Accessed June 6, 2014.
4. Ho ET, Wong G, Craig JC, Chapman JR. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. Transplantation. 2013;95(9): 1120-1128.
5. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs. 2011;71(12):1561-1577.
6. Tsunashima D, Kawamura A, Murakami M, et al. Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study. Clin Ther. 2014;36(5):748-759.
7. First MR, Fitzsimmons WE. Modified release tacrolimus. Yonsei Med J. 2004;45(6):1127-1131.
8. Tsuchiya T, Ishida H, Tanabe T, et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. Transplantation. 2013;96(2):198-204.
9. Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation. 2013;96(2):191-197.
10. Alloway RR, Eckhoff DE, Washburn WK, Teperman LW. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. Liver Transpl. 2014;20(5):564-575.
11. Min SI, Ha J, Kang HG, et al. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. Am J Transplant. 2013;13(8): 2191-2197.
12. Lapeyraque AL, Kassir N, Théorêt Y, et al. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatr Nephrol. 2014;29(6):1081-1088.
13. Méndez A, Berastegui C, López-Meseguer M, et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. Transplantation. 2014;97(3):358-362.
14. Stifft F, Stolk LM, Undre N, van Hooff JP, Christiaans MH. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. Transplantation. Epub December 13, 2013.
15. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005;79(4):499-502.
16. Niioka T, Kagaya H, Miura M, et al. Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. Eur J Clin Pharmacol. 2013;69(9): 1659-1665.
17. Wu MJ, Chang CH, Cheng CY, et al. Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5. Transplant Proc. 2014;46(2):403-405.
18. Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7(3):595-608.
19. Krämer BK, Charpentier B, Bäckman L, et al; Tacrolimus Prolonged Release Renal Study Group. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant. 2010;10(12): 2632-2643.
20. Srinivas TR, Kaplan B, Meier-Kriesche HU. The noninferiority trial: don't don't do it. Am J Transplant. 2010;10(12):2571-2573.
21. Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N; Optimising immunoSuppression After Kidney transplantation with ADVAGRAF Study Group. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96(10):897-903.
22. Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013;13(3):760-769.
23. Takahashi K, Abe R, Usuki S, So M. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. Transplant Proc. 2014;46(2):406-410.
24. Nakamura Y, Hama K, Katayama H, et al. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. Transplant Proc. 2012;44(1):124-127.
25. Lauzurica R, Morales JM, van Hooff J, Study Investigators. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus. Transpl Int. 2012;25(1):48-55.
26. Slatinska J, Rohal T, Wohlfahrtova M, Viklicky O. Long-term follow-up of stable kidney transplant recipients after conversion from tacrolimus twice daily immediate release to tacrolimus once-daily prolonged release: a large single-center experience. Transplant Proc. 2013;45(4): 1491-1496.
27. Wu SW, Tsai HC, Tsai PY, Hung TW, Chang HR, Lian JD. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients. Swiss Med Wkly. 2013;143:w13850.
28. Masutani K, Tsuchimoto A, Haruyama N, et al. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation. Transplant Proc. 2014;46(2):395-399.
29. Kitada H, Okabe Y, Nishiki T, et al. One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant. Exp Clin Transplant. 2012;10(6):561-567.
30. Trunečka P, Boillot O, Seehofer D, et al; Tacrolimus Prolonged Release Liver Study Group. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010;10(10):2313-2323.
31. Dumortier J, Guillaud O, Boillot O. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. Liver Transpl. 2013;19(5):529-533.
32. Weiler N, Thrun I, Eberlin M, et al. Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release? Transplant Proc. 2013;45(6):2321-2325.
33. Giannelli V, Rossi M, Giusto M, et al. Conversion from twice-daily to once-daily Tacrolimus administration in liver transplant patient: results of long term follow-up. Eur Rev Med Pharmacol Sci. 2013;17(20): 2718-2720.
34. Valente G, Rinaldi L, Sgambato M, Piai G. Conversion from twice-daily to once-daily tacrolimus in stable liver transplant patients: effectiveness in a real-world setting. Transplant Proc. 2013;45(3):1273-1275.
35. Meçule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc. 2010;42(4):1317-1319.
36. Sessa A, Esposito A, Iavicoli G, et al. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus. Transplant Proc. 2012;44(7):1901-1906.
37. Uchida J, Iwai T, Kabei K, et al. Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients. Transplant Proc. 2014;46(2):532-536.
38. Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2): 333-340.
39. Eberlin M, Otto G, Krämer I. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc. 2013;45(6):2314-2320.
40. Doesch AO, Mueller S, Akyol C, et al. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation. Drug Des Devel Ther. 2013;7:1253-1258.
41. Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85(6): 1404-1411.